Satterlee continues its role as an advisor to companies in the life sciences industry. The firm advised Y-mAbs Therapeutics, Inc. on its September 2018 initial public offering of 6,900,000 shares of common stock at a price of $16.00, including the full exercise of the underwriters’ option to purchase 900,000 additional shares, in which Y-mAbs raised approximately $110 million. Y-mAbs trades on the Nasdaq Global Select Market under the symbol “YMAB.”
Bank of America Merrill Lynch and Cowen and Company served as joint book-running managers for the offering.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Satterlee has represented Y-mAbs in other matters since its inception in April 2015, including its earlier funding rounds totaling approximately $120 million.
For more information, please see Y-mAbs press release.